Skip to Content
Biotechnology

A pill for covid

Easy to take pills that prevent severe covid-19 could work against the next pandemic, too.

February 23, 2022
Concept illustration of the covid pill
Andrea D'aquino

Key players

Merck, Pfizer, Pardes Biosciences

 

Availability

Now

Remember hydroxychloroquine, a malaria treatment taken by Donald Trump, and ivermectin, the horse dewormer that sent people to poison control? These drugs weren’t effective against covid-19. But people desperately wanted them to be. The dream was a pill you could swallow to make the virus go away. 

Now the real thing is here: pills designed from the ground up to block the covid-19 virus. And they work. Given to people within a few days of infection, an antiviral from Pfizer slashes the chance of hospitalization by 89%. The US government has already placed orders for $10 billion worth of the new drug, called Paxlovid.

The new pill was no lucky stab in the dark. Chemists designed it to mess with the virus’s ability to copy itself. The medicine locks onto and blocks a protein, called a protease, that’s at the core of covid’s menacing replication machinery. 

Similar protease enzymes exist in other types of coronavirus. That means Pfizer’s drug could also be a ready defense against the next pandemic. And scientists are sure that more pathogens like SARS-CoV-2 lurk in bat caves and industrial animal farms.

The new antiviral drugs—there’s also one from Merck that targets a different mechanism in the virus’s replication—took longer than covid vaccines to design, synthesize, and test. But they still set records. Never before has an entirely new molecule to defeat a disease gone so quickly from a chemist’s bench into the mouths of volunteers and gained approval from the US Food and Drug Administration. The CEO of Pfizer, Albert Bourla, said he was “in tears” when he got the news in November that the drug worked.

The pill will prevent many people from dying of covid-19, including people with weak immune systems for whom vaccines don’t work. And if a new variant turns up that defeats vaccines, antivirals could be our last resort.

As part of our 10 Breakthrough Technologies series, discover how covid pills were developed and what to expect next.

Deep Dive

Biotechnology

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

How do strong muscles keep your brain healthy?

There’s a robust molecular language being spoken between your muscles and your brain.

The quest to show that biological sex matters in the immune system

A handful of immunologists are pushing the field to take attributes such as sex chromosomes, sex hormones, and reproductive tissues into account.

This company is about to grow new organs in a person for the first time

A volunteer with severe liver disease will soon undergo a procedure that could lead them to grow a second liver.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.